Eledon Pharmaceuticals, Inc.

ELDN · Nasdaq · SIC 2834: Pharmaceutical Preparations
204
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the cent...

Next Earnings

Q2 FY2026 — expected 2026-08-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionELDNdiscussed_in_filing Cybersecurity
topic_mentionELDNdiscussed_in_filing Cybersecurity
topic_mentionELDNdiscussed_in_filing Healthcare & Bio
topic_mentionELDNdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001193125-26-116164EDGAR68K words
2025-03-202024-12-310000950170-25-042754EDGAR—
2024-03-282023-12-310000950170-24-038091EDGAR—
2023-03-302022-12-310000950170-23-011011EDGAR—
2022-03-242021-12-310001564590-22-011698EDGAR—
2021-03-312020-12-310001564590-21-016828EDGAR—
2020-03-172019-12-310001564590-20-011260EDGAR—
2019-03-282018-12-310001564590-19-009631EDGAR—
2018-04-022017-12-310001564590-18-007314EDGAR—
2017-03-032016-12-310001193125-17-069741EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-283275EDGAR50K words
2025-08-142025-06-300001193125-25-180906EDGAR—
2025-05-142025-03-310000950170-25-071582EDGAR—
2024-11-122024-09-300000950170-24-125622EDGAR—
2024-08-192024-06-300000950170-24-098590EDGAR—
2024-05-152024-03-310000950170-24-060025EDGAR—
2023-11-092023-09-300000950170-23-062203EDGAR—
2023-08-102023-06-300000950170-23-041456EDGAR—
2023-05-112023-03-310000950170-23-021372EDGAR—
2022-11-142022-09-300000950170-22-025007EDGAR—
2022-08-112022-06-300000950170-22-016935EDGAR—
2022-05-122022-03-310001564590-22-019921EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190001193125-26-116154EDGAR3K words
2026-01-020001193125-26-000968EDGAR—
2025-11-140001193125-25-283294EDGAR—
2025-11-130001193125-25-278392EDGAR—
2025-11-070001193125-25-270286EDGAR—
2025-08-140001193125-25-180820EDGAR—
2025-08-060000950170-25-103975EDGAR—
2025-06-120000950170-25-085588EDGAR—
2025-05-140000950170-25-071370EDGAR—
2025-04-070000950170-25-051663EDGAR—

204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001404281
TickerELDN
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 3fae32a978f9b06587743955cd7f35ec4f14f3b3c3ec234a55f4723faaa9da0e
parent: 76a0b57787f4cad9987175f31747320dd9cad48b0353a4de8c68fb65354f913e
content hash: b8b04e1970fc2f39482c0e0645d946237522c4adeac014e3d539cf43da9dfa01
signed: 2026-04-13T04:44:49.690Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf